Biopharmaceutics, pharmacokinetics and pharmacology of psoralens - PubMed (original) (raw)
Review
Biopharmaceutics, pharmacokinetics and pharmacology of psoralens
L M Stolk et al. Gen Pharmacol. 1988.
Abstract
The psoralen derivative 8-methoxypsoralen (8-MOP) and to a lesser extent some other psoralens, including 5-methoxypsoralen (5-MOP) and 4,5',8-trimethylpsoralen (TMP) have acquired a place in the treatment of psoriasis and other dermatoses. They are only active when combined with long-wave ultraviolet light: PUVA therapy (Psoralen plus UVA). Successful PUVA therapy depends on sufficiently high psoralen concentrations coinciding with the time of irradiation. The use of oral or rectal pharmaceutical formulations with 8-MOP dissolved in liquid is preferable to conventional tablets or capsules. Since no formulation of 5-MOP with fast and predictable absorption is available 8-MOP should be preferred in PUVA therapy. The effectiveness of oral TMP is doubtful, because of low serum concentrations, probably due to malabsorption.
Similar articles
- Psoralens percutaneous permeation across the human whole skin and the epidermis in respect to their polarity (in vitro study).
Saïd A, Makki S, Muret P, Humbert P, Millet J. Saïd A, et al. J Dermatol Sci. 1997 Feb;14(2):136-44. doi: 10.1016/s0923-1811(96)00561-0. J Dermatol Sci. 1997. PMID: 9039977 - Clinical pharmacokinetics of methoxsalen and other psoralens.
de Wolff FA, Thomas TV. de Wolff FA, et al. Clin Pharmacokinet. 1986 Jan-Feb;11(1):62-75. doi: 10.2165/00003088-198611010-00004. Clin Pharmacokinet. 1986. PMID: 3512141 Review. - Tracing the Photoaddition of Pharmaceutical Psoralens to DNA.
Diekmann J, Theves I, Thom KA, Gilch P. Diekmann J, et al. Molecules. 2020 Nov 10;25(22):5242. doi: 10.3390/molecules25225242. Molecules. 2020. PMID: 33182821 Free PMC article. - Mechanism of action of psoralens: isobologram analysis reveals that ultraviolet light potentiation of psoralen action is not additive but synergistic.
Yurkow EJ, Laskin JD. Yurkow EJ, et al. Cancer Chemother Pharmacol. 1991;27(4):315-9. doi: 10.1007/BF00685118. Cancer Chemother Pharmacol. 1991. PMID: 1998988 - Psoralens and related compounds in the treatment of psoriasis.
McEvoy MT, Stern RS. McEvoy MT, et al. Pharmacol Ther. 1987;34(1):75-97. doi: 10.1016/0163-7258(87)90093-3. Pharmacol Ther. 1987. PMID: 3310045 Review.
Cited by
- Effects of psoralens as anti-tumoral agents in breast cancer cells.
Panno ML, Giordano F. Panno ML, et al. World J Clin Oncol. 2014 Aug 10;5(3):348-58. doi: 10.5306/wjco.v5.i3.348. World J Clin Oncol. 2014. PMID: 25114850 Free PMC article. Review. - 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.
McNeely W, Goa KL. McNeely W, et al. Drugs. 1998 Oct;56(4):667-90. doi: 10.2165/00003495-199856040-00015. Drugs. 1998. PMID: 9806110 Review. - In vivo activation of human immunodeficiency virus type 1 long terminal repeat by UV type A (UV-A) light plus psoralen and UV-B light in the skin of transgenic mice.
Morrey JD, Bourn SM, Bunch TD, Jackson MK, Sidwell RW, Barrows LR, Daynes RA, Rosen CA. Morrey JD, et al. J Virol. 1991 Sep;65(9):5045-51. doi: 10.1128/JVI.65.9.5045-5051.1991. J Virol. 1991. PMID: 1908029 Free PMC article.